Reference: Campra, P. (2021). Graphene oxide detection in aqueous suspension: Observational study in optical and electron microscopy. Interim report (I). Universidad de Almería, Spain. Summary: This interim report details the microscopic analysis of a vial labelled “COMIRNATY™,” containing a cloudy aqueous suspension. Received on 06/10/2021, the sample underwent RNA extraction and quantification, revealing the presence […]
Reference: U.S. Department of Health and Human Services. (2021). Fact sheet for recipients and caregivers: Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 12 years of age and older. Retrieved from www.cvdvaccine.com Summary: The Pfizer-BioNTech COVID-19 Vaccine is offered under emergency use authorization (EUA) to prevent
Reference: Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., Marquez, P. L., Olson, C. K., Liu, R., Chang, K. T., Ellington, S. R., Burkel, V. K., Smoots, A. N., Green, C. J., Licata, C., Zhang, B. C., Alimchandani, M., Mba-Jonas, A., Martin, S. W., Gee, J. M.,
Reference: Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., … & Meaney-Delman, D. M. (2021). Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New England Journal of Medicine, 384(24), 2273-2282. https://doi.org/10.1056/NEJMoa2104983 Summary: The article evaluates the safety of mRNA Covid-19 vaccines in pregnant individuals, utilising
Reference: Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., Neuzil, K. M., Corey, L., Cauwenberghs, N., Tanner, T., Hardt,
Reference: South African Medical Research Council. (2021). Sisonke Protocol Version 4.4 dated 29 Apr 2021. Summary: The Sisonke Protocol is an open-label, single-arm phase 3B study aimed at evaluating the effectiveness of the Ad26.COV2.S COVID-19 vaccine among healthcare workers in South Africa. This study involves approximately 500,000 healthcare workers aged 18 and older, who will
Reference: VigiAccess. (2021). VigiAccess™. Retrieved from https://who-umc.org Summary: VigiAccess provides a comprehensive overview of adverse drug reactions (ADRs) associated with Covid-19 vaccines, highlighting a total of 2,183,912 reports. The data illustrates the geographical distribution of ADRs, with significant counts reported across continents such as the Americas, Europe, and Asia. The analysis categorises ADRs into various
Reference: Nakagami, H. (2021). Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 33(10), 521–527. https://doi.org/10.1093/intimm/dxab013 Summary: The article discusses the urgent development of COVID-19 vaccines in response to the SARS-CoV-2 outbreak. Various vaccine technologies are being explored, categorised into four main groups: intact target viruses, proteins, viral vectors, and nucleic acids. RNA and
Reference: Seneff, S., & Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1), 38-58. Summary: The article by Seneff and Nigh reviews the mRNA vaccines developed for COVID-19, primarily focusing on the Pfizer and Moderna vaccines. While
Reference: Centres for Disease Control and Prevention. (2021, March 4). Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html Summary: mRNA vaccines represent a novel approach to immunisation against infectious diseases, including COVID-19. They work by instructing cells to produce a harmless piece of the virus’s spike protein, eliciting an immune response without introducing the live virus. This process